Method Article

Isolation of Cancer Stem Cells From Human Prostate Cancer Samples

14K views

DOI:

10.3791/51332

March 14th, 2014

In This Article

Summary

The isolation of cancer stem cells (CSCs) directly from human tissues is requisite for their biological characterization. This manuscript describes a methodology for the isolation of prostate CSCs from human tissues, while also providing tips on troubleshooting difficult steps.

Abstract

The cancer stem cell (CSC) model has been considerably revisited over the last two decades. During this time CSCs have been identified and directly isolated from human tissues and serially propagated in immunodeficient mice, typically through antibody labeling of subpopulations of cells and fractionation by flow cytometry. However, the unique clinical features of prostate cancer have considerably limited the study of prostate CSCs from fresh human tumor samples. We recently reported the isolation of prostate CSCs directly from human tissues by virtue of their HLA class I (HLAI)-negative phenotype. Prostate cancer cells are harvested from surgical specimens and mechanically dissociated. A cell suspension is generated and labeled with fluorescently conjugated HLAI and stromal antibodies. Subpopulations of HLAI-negative cells are finally isolated using a flow cytometer. The principal limitation of this protocol is the frequently microscopic and multifocal nature of primary cancer in prostatectomy specimens. Nonetheless, isolated live prostate CSCs are suitable for molecular characterization and functional validation by transplantation in immunodeficient mice.

Introduction

Intratumoral heterogeneity is considered to be a hallmark of cancer1. Indeed, several mechanisms of intratumoral heterogeneity have been described, including genetic mutation and interactions with the microenvironment. In addition, some cancers may contain a cellular hierarchy with a subpopulation of cancer stem cells (CSCs) that exhibits the properties of tumor-initiating capacity and self-renewal in serial transplantation assays2-5. Initially described in hematological6, breast7, and brain8 malignancies, CSCs have also been studied in prostate cancer9-12 as well as other tumor types2-5.

....

Access restricted. Please log in or start a trial to view this content.

Protocol

1. Harvesting and Processing of Human Prostate Cancer Tissue from Surgical Specimens

  1. Prepare two 50 ml polystyrene conical tubes containing 15 ml of Roswell Park Memorial Institute (RPMI) 1640 culture medium supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin.
  2. Pathology service personnel harvest primary and metastatic prostate cancer samples from prostatectomy and palliative surgery specimens, respectively, under an Institutional Review Board approved protocol. Metastatic samples may be obtained from lymph node dissections during primary surgery, the vertebrae during palliative surgical procedures, such as....

Access restricted. Please log in or start a trial to view this content.

Results

Histology and flow cytometry analysis; tumor tissue section, cell population graph, data comparison.
Figure 1. Human prostate cancer tumor harvesting and flow cytometry plot illustrating specific populations from a human prostate cancer. (A) Tumor nodules are har.......

Access restricted. Please log in or start a trial to view this content.

Discussion

This protocol describes the isolation of CSCs from fresh human prostate cancer tissues. Several important considerations influence the successful outcome of this protocol.

The recovery of high numbers of viable prostate cancer cells is dependent on careful gross assessment of surgical samples. In our experience, the successful isolation of tumorigenic prostate cells is best assured when macroscopic tumor nodules are observed and processed10.

However, nowa.......

Access restricted. Please log in or start a trial to view this content.

Disclosures

No conflicts of interest declared.

Acknowledgements

This work was supported by the Hariri Family Foundation and the TJ Martell Foundation.

....

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
RPMIGibco Life Technologies11875-093
Fetal bovine serumGibco Life Technologies10437-028
Penicillin StreptomycinGibco Life Technologies15140-122
PBSCorning Cell Gro21-031-CM
60 mm, 15 mm Cell culture dishCorning3295
35 µm Cell StrainerBD Falcon352340
50 ml conical tubeCrystalgen23-2263
15 ml conical tubeCrystalgen23-2265
Red blood cell lysing bufferSigmaR7757
HLA class I (W6/32) PE antibodyAbcamab43545
CD31 FITC antibodyeBioscience11-0319-42
CD45 FITC antibodyAbcamab27287
IgG2aκ PE antibodyBD Pharminogen555574
IgG1κ FITC antibodyBD Pharminogen551954
DAPIInvitrogend3571
12 mm x 75 mm Polystyrene tubes with cell strainer capBD Falcon352235
Vortex MixerCrystalgenCG-BV1000
10% Neutral Buffer FormalinFisherRBBP-0480

References

  1. Hanahan, D., Weinberg, R. A. Hallmarks of cancer: the next generation. Cell. 144, 646-674 (2011).
  2. Magee, J. A., Piskounova, E., Morrison, S. J. Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell. 21, 283-296 (2012).
  3. Nguyen, L. V., Vanner, R., Dirks, P., Eaves, C....

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Request permission to reuse the text or figures of this JoVE article

Request Permission

Tags

Flow CytometryHLA Class ICell IsolationTissue DissociationFluorescent LabelingXenotransplantationGene Expression ProfilingImmunodeficient Mice

Related Articles